Skip Navigation Links
22 June 2021

Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer

Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer

The OCT ‘Meet the Team’ series is intended to give you a snapshot of the people behind the business, providing more of an insight into what we do and why we are so passionate about our work.

With nearly a month having passed since OCT’s float on the London Stock Exchange, we wanted to get some time with the company’s CEO, Dr John Lucas, and provide a bit of an insight into the person leading this newly listed pharmaceutical company, on his career and his motivations.

Interviewer: John - you’re a busy man, so many thanks for your time today.

John: My pleasure, James.

Interviewer: You were promoted from Chief Commercial Officer to Chief Executive Officer in January this year. How has it been settling into this new role, especially while the company has been going through such a major equity transaction and development from a limited company to a plc?

John: “It has definitely been a busy few months and our float on the London Stock Exchange is a testament to the quality of the team and our partners.

Interviewer: I’m interested to hear more about what drew you to OCT, both as a business model and a concept, and also what drove you from a personal perspective?

John: “It’s a combination of factors. I saw the opportunity to develop cannabinoids, in what I would consider, the right way – as licensed prescription medicines. I was drawn by the opportunity to build a company whose mission is to help patients in need. The patients we aim to help are those in pain. I am not talking about the sort of pain that you can relieve with over-the-counter medicines. The indications we are targeting are those where people are really suffering. And that is very motivating.

Interviewer: You obviously feel very passionate about the work that you are doing at OCT. What are your expectations for the potential that OCT has to change people’s lives for the better?

John: “Indeed, we are extremely passionate about our work and motivated by the opportunity to make a meaningful difference to the lives of people in pain. The current pandemic is rightly front and centre, but we should not forget the silent pandemic which is pain. Patient associations are pleading for novel therapeutic approaches because the options for people in life-altering pain are so limited. We have an opioid crisis on our hands because for many, opioids are the only available option. Our job is to make the world a better place by giving people who are suffering their lives back. It doesn’t get any better than that.”

Interviewer: In the nearly three years with OCT, you undoubtedly will have seen this company grow significantly, whether it be the series of fundraises, or further development of the drug candidate pipeline. The float in May surely will have opened some doors. What would you say is the company’s next major milestone, now this has happened?

John: “The funds raised by the IPO allows us to do the job we came here to do, and that is a great feeling for all of us. The focus for us now is all about progressing our four drug programs. Our aim is to progress our first two drug programmes through Phase 1 clinical trials by the end of this funding round. We also aim to progress our third program to preclinical stage and a fourth programme from discovery stage to a lead candidate. As I’m sure you’ve gathered, we are quite ambitious, and expect to make great strides in the next 12 to 24 months.”

Interviewer: There has undoubtedly been change in perception and attitude towards cannabinoid-based therapies over the last few years from regulators, media and the public. How would you describe this change?

John: “The public is increasingly more willing to try cannabinoid-based medicines for their pain conditions. The problem currently is the lack of licensed cannabinoid-based medicines. Unlicensed medical cannabis is available in the US and UK, but there are problems. Doctors in the US cannot prescribe medical cannabis unless it is approved by the FDA. They can recommend it although they are very reluctant to do so. In the UK, some specialists can prescribe medical cannabis, in limited situations, but again they are reluctant to do so. In both cases the reluctance is for good reason. Medical cannabis producers shift the burden that would normally be the responsibility of them, the manufacturer, to the physician, and ultimately to the patient. With no oversight from a medicines regulatory agency like the FDA and MHRA, physicians must take on the responsibility that the unapproved product is both safe and effective and produced in a quality and dose-consistent manner. Understandably, most physicians say no. We understand the need for any medicine to undergo the full drug development process ending with license and oversight from a medicines regulatory agency. I recognize that I am at odds with the medical cannabis community in this regard.

Most of us take a few or even several different drug products over the course of a given year. We swallow a pill and don’t give a second thought about whether it’s safe and effective, or that the dose and quality are the same every time. This is because we know there is an agency like the FDA or MHRA with thousands of experts who do that for us. But what if there is not?

So, in case you are not convinced, let me leave you with a question: The next time you take a medicine or administer one to your child or loved one, think about all the rigorous testing and oversight that went to the development of that drug and ask yourself; does that matter?”

I think your answer will explain why OCT is here.

Interviewer: Thank you for taking the time to speak with us. It has been great to get to hear your thoughts on developments at OCT, and in the sector more widely, and we look forward to further updates soon.

Related News articles

  • Oxford Cannabinoid Technologies "ready to go" after phase 1 trial submission

    06 January 2023 Proactive Interview
  • Oxford Cannabinoid Technologies nearly ready for new Phase 1 trial

    14 November 2022 Proactive Interview
  • StockBox Premiere - Oxford Cannabinoid Technolgies - Programme 1

    06 October 2022 StockBox
  • StockBox Interview - Oxford Cannabinoid Technologies w/ Dr Valentino Parravicini, CSO

    05 October 2022 StockBox
  • StockBox Premiere with Oxford Cannabinoid, Poolbeg Pharma & Destiny Pharma

    05 October 2022 StockBox
  • Cannabinoid Medicine for Pain Treatment with Clarissa Sowemimo-Coker COO Oxford Cannabinoid

    22 August 2022 StockBox
  • Oxford Cannabinoid Technologies has good opportunities in both lead products says analyst

    26 July 2022
  • Outsourcing in Clinical Trials UK & Ireland 2022 Conference – Dr Valentino Parravicini’s Address

    20 June 2022 Conference
  • OCT Investor Update 30 May 2022 - Q&A Questions

    30 May 2022 Investor Questions
  • The Cannabis Conversation: Cannabis Vs. Opioids with Valentino Parravicini

    18 May 2022 Podcast
  • Investor Meet Company Q&A Session

    16 May 2022 Investor Meet
  • Oxford Cannabinoid Technologies Announces Formation of Scientific Advisory Board to Support Clinical Strategy

    25 April 2022 Scientific Advisory Board
  • Updates on Lead Programme 1 (OCT461201) and Programme 2 (OCT130401) - Trigeminal Neuralgia Clinical Trial

    31 March 2022 Programme Update
  • Data from pre-clinical study show positive results

    08 March 2022 Research Update
  • Requisition of General Meeting - Update

    04 March 2022 General Meeting
  • Oxford Cannabinoid Technologies aims to get aggressive share of £42.5bln market by 2027

    24 February 2022
  • Requisition of General Meeting

    18 February 2022 General Meeting
  • Notice of Analyst and Investment Presentation - How to Register

    17 February 2022 Presentations
  • Oxford Cannabinoid Technologies in drug development deal with Oxford StemTech

    18 November 2021 StemTech
  • Oxford Cannabinoid Technologies in drug development deal with Oxford StemTech

    17 November 2021 R&D Support
  • Posting of Annual Report, Notice of AGM and Form of Proxy

    27 October 2021 Annual Report, Notice of AGM and Form of Proxy
  • OCT Results and Company Update

    18 October 2021 Results and Company Update
  • Final Results and Notice of Annual General Meeting 13th October 2021

    13 October 2021 RNS
  • Oxford Cannabinoid Technologies work on treatment for chronic, painful disease Trigeminal Neuralgia

    12 October 2021 Trigeminal Neuralgia Interview
  • Oxford Cannabinoid Technologies Targets Chronic Pain Condition with Latest Formulation

    11 October 2021 Program 2 Announcement
  • OCT Explore the Opioid Crisis and Chronic Pain Pandemic in Pharmafocus Magazine

    30 September 2021 Pharmafocus Article
  • Good shape, good budget and on track for Oxford Cannabinoid Technologies Holdings

    28 September 2021 Podcast
  • Oxford Cannabinoid Technologies' deal for exclusive access to Canopy Growth's cannabinoid library

    22 September 2021 Canopy Growth
  • Oxford Cannabinoid Technologies says admission to the OTCQB is a logical next step

    02 September 2021 US Market
  • Oxford Cannabinoid Technologies announces strategic partnership with Evotec

    06 July 2021 Partnership
  • Chief Scientific Officer Valentino Parravicini to speak at major cannabinoid-based drugs summit in Boston, Massachusetts

    Chief Scientific Officer Valentino Parravicini to speak at major cannabinoid-based drugs summit in Boston, Massachusetts

    24 June 2021 iCDP Speaker
  • Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer

    Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer

    22 June 2021 Meet the Team Interview Series
  • Oxford Cannabinoid Technologies Holdings plc to conduct live presentations to retail investors

    04 June 2021 Live Presentation
  • OCT Forges Partnership with Voisin Consulting Life Sciences

    OCT Forges Partnership with Voisin Consulting Life Sciences

    01 June 2021 OCT Partnership
  • Oxford Cannabinoid Technologies Announces Changes to Executive Team

    11 January 2021 Oxford Cannabinoid Technologies Announces Changes to Executive Team
  • OCT Company Values: How We Pursue Our Mission and Vision

    OCT Company Values: How We Pursue Our Mission and Vision

    01 December 2020 OCT Company Values
  • OCT - Meet the Team Interview Series: Valentino Parravicini, Chief Scientific Officer

    Meet the Team Interview Series: Dr Valentino Parravicini, Chief Scientific Officer

    26 October 2020 Meet the Team Interview Series
  • OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain

    07 September 2020 OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain
  • OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer as the business prepares for exciting new developments

    OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer

    28 July 2020 OCT Press Release
  • Cannabinoids in medicine part 5: Treating COVID-19

    17 June 2020 Open Access Government
  • Why the Government should continue to invest in Life Sciences post COVID-19

    Why the government should continue to invest in Life Sciences post COVID-19

    01 June 2020 OCT blog - John Lucas, COO
  • OCT researchers publish new study examining genes involved in treating neuropathic pain

    19 April 2020 OCT Press Release
  • OCT announces pre-clinical development of new cannabinoid compound ‘OCT461201’ to treat IBS

    03 April 2020 OCT Press Release
  • Cannabinoids in medicine part 4: Epilepsy

    30 March 2020 Open Access Government
  • Cannabinoids in Medicine Part 3: Psoriasis and Rheumatoid Arthritis

    07 January 2020 Open Access Government
  • Cannabinoids in medicine Part 2: Pain

    11 October 2019 Open Access Government
  • Cannabinoids in medicine Part 1: Cancer

    22 August 2019 Open Access Government
  • An interview with Neil Mahapatra

    08 January 2019 The Times Magazine
  • High life: the start-up hoping to unlock the secrets of medical cannabis

    09 August 2018 Evening Standard
  • Oxford Cannabinoid Technologoies goes global as it announces close of series a fundraising round and management team line-up

    28 June 2018 OCT Press Release
  • Embracing the medical potential of cannabinoids

    01 June 2017 The Medicine Maker
  • Smashing the stigma with science

    01 June 2017 The Medicine Maker
  • Oxford University launches £10m research project into medical marijuana

    16 March 2017 Evening Standard
  • Oxford University launches £10m marijuana research programme

    16 March 2017 BBC
  • Oxford University to launch multimillion-dollar medical marijuana research program

    16 March 2017 CNBC
  • Oxford University to launch study on medical benefits of marijuana

    16 March 2017 The Telegraph
  • The University of Oxford and Kingsley Capital Partners announce ground breaking Cannabinoid Biomedicine Research Programme

    15 March 2017 OCT Press Release